EUVIMEDObjevte EUVIMED
Systematische Übersicht

The impact of dupilumab on skin barrier function: A systematic review

Trinidad Montero-Vilchez iD, Raquel Sanabria-de-la-Torre, Manuel Sanchez-Diaz iD, Clara Ureña-Paniego, Alejandro Molina-Leyva iD, Salvador Arias-Santiago

Journal of the European Academy of Dermatology and Venereology · 2023

DOI: 10.1111/jdv.19081 ↗

At a glance

Systematische Übersicht in Journal of the European Academy of Dermatology and Venereology, 2023. Written by Trinidad Montero-Vilchez and 5 co-authors. Institution: Dermatology Department, Virgen de las Nieves University Hospital, Granada, Spain. Major MEDLINE topics: Water Loss, Insensible, Dermatitis, Atopic. Cited 23 times so far (Crossref); 45 references.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Skin barrier dysfunction plays an important role in atopic dermatitis (AD) aetiopathogenesis. Dupilumab, a drug that inhibits IL‐4 and IL‐13, is an effective treatment for AD but there is scarce evidence about its impact on epidermal barrier. The objective of this systematic review is to evaluate the influence of dupilumab on skin barrier in patients with AD using non‐invasive tools. A systematic review was designed following PRISMA guidelines. The literature search identified 73 references and, finally, only 6 were selected, including a total of 233 participants. All the studies were prospective observational studies. Dupilumab improved clinical scores in all the research. Skin barrier function parameters were mainly measured on the volar forearm. Transepidermal water loss (TEWL) was the parameter most frequently measured, evaluated in all the studies. Dupilumab decreased TEWL on eczematous lesions and non‐involved skin. About 33.6% (2/6) studies reported that dupilumab also increased stratum corneum hydration (SCH) on eczematous lesions while one study did not report any changes in this parameter. This drug also decreased temperature and improved ceramide composition. In conclusion, dupilumab improved skin barrier function in AD patients, mainly reflected in a decreased in TEWL values.

Subjects

MeSH terms (MEDLINE)

Water Loss, InsensibleDermatitis, AtopicHumansSkinEpidermisObservational Studies as TopicAntibodies, Monoclonal, Humanized

Substances

dupilumabAntibodies, Monoclonal, Humanized

Authors and institutions

  • Dermatology Department, Virgen de las Nieves University Hospital, Granada, Spain.
  • Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, Spain.
  • Dermatology Department, Faculty of Medicine, University of Granada, Granada, 18001, Spain.

ORCID profiles: Trinidad Montero-Vilchez, Manuel Sanchez-Diaz, Alejandro Molina-Leyva

Cite

APA

Montero-Vilchez, T., Sanabria-de-la-Torre, R., Sanchez-Diaz, M., Ureña-Paniego, C., Molina-Leyva, A., & Arias-Santiago, S. (2023). The impact of dupilumab on skin barrier function: A systematic review. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.19081

Vancouver

Montero-Vilchez T, Sanabria-de-la-Torre R, Sanchez-Diaz M, Ureña-Paniego C, Molina-Leyva A, Arias-Santiago S. The impact of dupilumab on skin barrier function: A systematic review. Journal of the European Academy of Dermatology and Venereology. 2023. doi:10.1111/jdv.19081

BibTeX
@article{MonteroVilchez2023,
  author = {Montero-Vilchez, Trinidad and Sanabria-de-la-Torre, Raquel and Sanchez-Diaz, Manuel and Ureña-Paniego, Clara and Molina-Leyva, Alejandro and Arias-Santiago, Salvador},
  title = {The impact of dupilumab on skin barrier function: A systematic review},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2023},
  doi = {10.1111/jdv.19081}
}
Start for free →